



NOVEMBER 2021
ANNUAL
GENERAL
MEETING

BOD AUSTRALIA LIMITED (ASX: BOD)

DISCLAIMER

This presentation has been prepared by Bod Australia Limited (Bod) and contains background information about Bod current at the date of this presentation. The presentation is in summary form and does not purport to be all-inclusive or complete. Recipients should conduct their own investigations and perform their own analysis in order to satisfy themselves as to the accuracy and completeness of the information, statements and opinion contained in this presentation.

This presentation is for information purposes only. Neither this presentation nor the information in it constitutes an offer, invitation, solicitation or recommendation in relation to the purchase or sale of shares. This presentation does not constitute investment advice and has been prepared without taking into account the recipient's investment objectives, financial circumstances or particular needs and the opinions and recommendations in this presentation are not intended to represent recommendations of particular persons. Recipient should seek professional advice when deciding if an investment is appropriate.

All securities transactions involve risk, which include (amongst others) the risk of adverse or unanticipated market, financial or political developments. To the fullest extent permitted by law, Bod and their officers, employees, agents and advisers do not make any presentation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of any information, statement, opinions, estimates, forecasts or other representations contained in this presentation. No responsibility for any error or omissions from this presentation arising out of negligence or otherwise is accepted.

This presentation may include forward-looking statements. Forward-looking statements are only predications and are subject to risk, uncertainties and assumptions that are outside the control of Bod. Actual values, results or events may be materially different to those expressed or implied in this presentation. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. Subject to any continuing obligations under the applicable law and ASX Listing Rules, Bod do not undertake any obligations to update or revise any information or any of the forward-looking statements in this presentation of any changes in events, conditions or circumstances on which any such forward-looking statement is based.


Non-IFRS measures:

We supplement our financial information reporting determined under International Financial Reporting Standards (IFRS) with certain non-IFRS financial measures, including cost of goods sold and earnings before interest, tax, depreciation and amortisation (EBITDA). We believe that these measures provide meaningful information to assist management, investors and analysts in understanding our financial results and assessing our prospects for future performance. Non-IFRS measures have not been subject to audit or review.

This presentation has been authorised for release by the Chief Executive Officer of Bod Australia Limited.

A LEADING LIFE SCIENCE AND HEALTHCARE COMPANY

3



INVESTMENT HIGHLIGHTS

4

A cannabis focused life science and healthcare company with **two established operating divisions**

Product pipeline and commercialisation
underpinned by R&D and clinical trials

Growing revenue profile
– FY2021 revenue increased 25% on FY2020 to \$7.5m

Revenue uplift continued in Q1 FY2022
– sales of \$1.67m, a 43% increase on Q4 FY2021

Net loss continues to decrease year on year
– Bod has an ongoing focus on reducing cash outflows

Established international footprint underpinning growth and exposure to large markets

Cash balance of \$6.18m (at 30 September 2021) leaves **company well placed for growth**


CORPORATE SNAPSHOT

5

CAPITAL STRUCTURE

SHARES ON ISSUE	105.9M
MARKET CAP	\$27.5M AT \$0.26 PER SHARE
CASH	\$6.18M AS AT 30 SEPT 2021
DEBT	NIL
52 WEEK HIGH/LOW	\$0.74 / \$0.23

ONGOING TOPLINE GROWTH



SUBSTANTIAL SHAREHOLDERS




NEW H2 LIMITED	14.03%
SG HISOCK & COMPANY LIMITED	9.64%
MS JO PATTERSON	6.18%
AWJ FAMILY PTY LTD	5.35%
MR CRAIG WELLER	4.58%
SANLAM PRIVATE WEALTH	2.36%
GP SECURITIES	2.15%

BOARD AND MANAGEMENT



MARK MASTERSON
Non-Executive Chairman



JO PATTERSON
Chief Executive Officer



GEORGE LIVERY
Non-Executive Director



AKASH BEDI
Non-Executive Director



HANNO CAPPON
Non-Executive Director



SIMON O'LOUGHLIN
Non-Executive Director

AS OF 20 AUGUST 2021

TWO CORE OPERATING BUSINESS DRIVING REVENUE GROWTH

MEDICINAL CANNABIS

Bod is focused on growing sales of its medicinal cannabis product, MediCabilis in Australia and the UK with other market entries pending

Multiple trials into the use of MediCabilis, Bod's cannabis products, are ongoing and building a body of evidence which focus on treatment areas including chronic pain, mental health, insomnia and other areas for patients with resistant specific conditions

Bod is also developing a low dose CBD product for the Australian Schedule 3 market

Additional R&D and collaboration work is ongoing with leading medical institutions – increasing the body of evidence for medicinal cannabis and treatment specific data

A growing suite of IP being developed for future product commercialisation and licencing agreements



CBD WELLNESS

All products licensed to Swisse Wellness parent company, Health and Happiness International Limited (H&H) (HKSE: 1112)

Bod generates revenue through royalty on product sales and a 'cost plus margin' on supply of CBD extract and formula

Bod delivers product innovations to support launches across international markets

30+ products in market sold under H&H brands (Swisse Wellness and CBII) with 10+ expected in CY2022

Products now being sold and distributed in the UK, Italy, Netherlands, Australia and the USA*

Bod to benefit from reoccurring revenue and new market entries



ONGOING R&D UNDERPINS COMMERCIAL OPPORTUNITIES ACROSS THE GROUP

Bod's purpose is to lead the field in product innovation, brought about from a deep understanding of plant medicines, specifically cannabis. This is supported by data collected and analysed from multiple R&D programs, focusing on a science led approach, unlocking opportunities that deliver better patient and consumer outcomes.

Bod's work in the area of science and R&D is supported by leading researchers and a medical advisory board with expertise in genetics, extraction and product development.

Bod partners with leading organisations to harness the health benefits of the cannabis plant and its other compounds to build a portfolio of innovative products that can be utilised in multiple categories and across multiple conditions.

R&D initiatives underway including:



Australian Schedule 3 Clinical Trial: Phase IIb clinical trial in collaboration with the Woolcock Institute to develop new low dose CBD product for Australia's over-the-counter market.



Drug Science Collaboration: Agreement secured to test the efficacy of Bod's medicinal cannabis product on symptoms associated with the long-term effects of COVID-19, referred to as Long-COVID.



Australia-wide medicinal cannabis study: National, multi-clinic observational study into the effectiveness of Bod's medicinal cannabis range for indications including anxiety, insomnia and PTSD. Interim results expected in the coming months.



Ongoing work with University of Technology Sydney (UTS): Following the discovery of a novel family of proteins that provide antioxidant protective effects when applied to skin cells, Bod lodged a patent application and has commenced additional test work with UTS to progress product development and commercialisation.



AN ESTABLISHED INTERNATIONAL FOOTPRINT IN MEDICINAL CANNABIS, CBD WELLNESS AND R&D

8

UK

MEDICINAL CANNABIS
CBD WELLNESS
R&D INITIATIVES



NEW TARGET MARKETS IN CY2022

IRELAND
DENMARK

NETHERLANDS
CBD WELLNESS

ITALY
CBD WELLNESS




US

CBD WELLNESS



AUSTRALIA
MEDICINAL CANNABIS
CBD WELLNESS
R&D INITIATIVES



RECENT MEDICINAL CANNABIS DIVISION GROWTH

Bod’s medical cannabis product range, under MediCabilis is being sold to patients in Australia and the UK

MediCabilis is being used by patients living with treatment resistant conditions including anxiety, insomnia and chronic pain

During FY2021 ~65% of Australian patients were repeat users – evidence of medicine quality and patient satisfaction


Medicinal cannabis product sales during FY2021 were up 40% to \$2.4m with sales expected to increase

During Q1 FY2022, Australian prescription sales grew 15% on the previous corresponding period

Growth being achieved in the UK – Q1 FY2022 prescription sales increased 53% on last quarter and 232% on the previous corresponding period

Bod held 52% market share of the total Australian market for full plant, high CBD products during October 2021

Growth expected to increase over coming months as the total Australian market continues to grow and UK operations scale up



SCHEDULE 3 (PHARMACIST ONLY) CBD OPPORTUNITY

10

Bod will become one of the first companies to introduce a Schedule 3 (Pharmacist Only) CBD product in Australia

Follows recent TGA decision allowing low dose CBD products to be sold over-the-counter by a pharmacist to consumers without a prescription

Unlocks a market valued at an estimated \$250m - unregulated market valued at ~\$3.5Bn highlighting potential product demand

Bod has entered into an agreement with Australia's leading research group the Woolcock Institute as the lead investigator of the trial

Collaboration allows Bod to progress a phase IIb clinical trial to test the efficacy of its unique CBD Product on symptoms associated with sleeplessness

Patient recruitment expected to start in January 2022 with the 12 week trial expected to commence February 2022

Following completion of the trial and receipt of an ARTG registration through the TGA, Bod will commercialise the product(s) in collaboration with multiple partners



CBD WELLNESS PRODUCT DIVISION PROGRESS

11

30+ products launched in 5 global markets in the last 2 years


Focus is on building awareness for the brand and category, expanding distribution and achieving revenue growth witnessed through reoccurring sales

Products being sold and distributed in Australia, UK, Italy and the Netherlands

Business division generated \$4.4m in revenue during FY2021 – a 13% increase on FY2020 (FY2020: \$3.9m)


First sales in US anticipated in December 2021 with growth and new products expected to launch in 2022

Ongoing growth expected from international expansion, increased sales in existing markets and new product launches



MULTIPLE NEAR TERM GROWTH CATALYSTS THROUGHOUT FY2022

12





THANK YOU

Level 1, 377 New South Head Road
Double Bay NSW 2028

+612 9199 5018

bodaustralia.com
bodpharmaceuticals.com



APPENDIX 1: BOARD & MANAGEMENT

14

MARK MASTERSON

Non-Executive
Chairman

Mark boasts two decades of experience in the pharmaceutical and healthcare sectors.

He began his career with Johnson & Johnson before joining global healthcare giant, Abbott Laboratories where he held multiple senior positions.

He also held the role of CEO with Australia's largest private diagnostic imaging network, I-MED. Following the acquisition of I-MED, he was appointed Chairman of Medicines Australia.

JO PATTERSON

Chief Executive
Officer

Jo is a CEO and Managing Director with over 20 years' in business and corporate strategy with exposure both in Australia and overseas. She has developed a number of businesses from start-up as well as driving established organisations towards growth and merger trajectories.

She has been officially recognised as a successful business executive by winning a number of key business awards and her acumen is evidenced in the success of previous companies in the technology, advertising and beauty sectors. Jo has held multiple CEO and Managing Director roles over her career.

These wide and diverse experiences led her to establish Bod Australia in 2014 and subsequently list the business on the ASX in 2016.

GEORGE LIVERY

Non-Executive
Director

George has ~30 years' experience domestically and internationally.

His experience most notably culminated with Swisse Wellness Group, where he was instrumental in negotiating the \$1.67B transaction with Biostime (H&H Group) and leading the corporate integration and strategy of the companies post transaction.

AKASH BEDI

Non-Executive
Director

Akash is Chief Strategy & Operations Officer at H&H Group.

He is based in Hong Kong and is responsible for leading H&H Group's strategy and business development including M&A and strategic investments for NewH2.

He has extensive experience in investing in global start-ups and high growth companies.

HANNO CAPPON

Non-Executive
Director

Hanno is currently Chief Technology Officer at H&H, a position which he has held since January 2021.

He has an extensive background in chemistry, life sciences, nutrition and health innovation and developing new consumer and healthcare solutions for commercialisation.

Hanno's previous senior roles with large international companies include VP R&D Nutritionals & Digestive Health at Bayer Consumer Health, Switzerland, as well as VP R&D Nutricia Medical Nutrition at leading multinational food company Danone Nutricia, Netherlands, amongst others.

SIMON O'LOUGHLIN

Non-Executive
Director

Simon is the founder of Australian based commercial law firm, O'Loughlins.

He has unparalleled experience in commercial and corporate law and also holds accounting qualifications.

Simon has extensive experience with ASX-listed companies and was the former Chairman of the Taxation Institute of Australia (SA Division).

APPENDIX 2: AN INDUSTRY LEADING SCIENTIFIC ADVISORY BOARD

15

ASSOCIATE PROFESSOR ARMAN SABET MD, FRACP

A medical doctor and the Head of the Neurology Department at Gold Coast University Hospital and an Associate Professor of Neurology at Griffith University.

Dr Sabet specialises in the treatment and management of neurological disorders, with a special interest in the utility of medicinal cannabis in clinical settings to help give patients the improved quality of life.

Dr Sabet will provide crucial clinical insight and valuable expertise into neurological disorders.

PROFESSOR ANDREW MCLACHLAN AM, PHD

Head of School and Dean at the Sydney Pharmacy School, The University of Sydney.

Professor McLachlan is a trained pharmacist, university academic and scientific researcher with experience in clinical pharmacology and the quality use of medicines.

Professor McLachlan is the former chair of a human research ethics committee and serves on Australian government committees related to medicines policy, evaluation, regulation and antidoping.

Professor McLachlan will provide invaluable expertise on clinical pharmaceutical research as well as the processes around drug development.

PROFESSOR IAN OLVER AM, MD, PHD


Currently a Professorial Research Fellow in the School of Psychology at the University of Adelaide.

Professor Olver trained as a medical oncologist and bioethicist, his current research focuses on supportive care in cancer and psycho-oncology.

Professor Olver was previously CEO of Cancer Council Australia and Clinical Director of the Royal Adelaide Hospital Cancer Centre.

Professor Olver's extensive experience and history in oncology practice and research will be invaluable for the research and development of cannabinoid therapeutics.

APPENDIX 3: PEER COMPARISON



COMPARISON IS BASED ON INTERNAL CALCULATIONS UTILISING MOST RECENT FULL YEAR RESULTS AND MARKET CAPITALISATION AS AT 17 NOVEMBER 2021.